These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25876451)

  • 81. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
    Wolinsky JS; Narayana PA; Nelson F; Datta S; O'Connor P; Confavreux C; Comi G; Kappos L; Olsson TP; Truffinet P; Wang L; Miller A; Freedman MS;
    Mult Scler; 2013 Sep; 19(10):1310-9. PubMed ID: 23447359
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
    Filippi M; Wolinsky JS; Comi G;
    Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
    O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS;
    N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951
    [TBL] [Abstract][Full Text] [Related]  

  • 85. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
    Pakpoor J; Disanto G; Altmann DR; Pavitt S; Turner BP; Marta M; Juliusson G; Baker D; Chataway J; Schmierer K
    Neurol Neuroimmunol Neuroinflamm; 2015 Dec; 2(6):e158. PubMed ID: 26468472
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
    Oh J; Walker B; Giovannoni G; Jack D; Dangond F; Nolting A; Aldridge J; Lebson LA; Leist TP
    Mult Scler J Exp Transl Clin; 2021; 7(3):20552173211024298. PubMed ID: 34345436
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M;
    N Engl J Med; 2012 Mar; 366(11):1000-9. PubMed ID: 22417253
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
    Havrdova E; Giovannoni G; Stefoski D; Forster S; Umans K; Mehta L; Greenberg S; Elkins J
    Mult Scler; 2014 Apr; 20(4):464-70. PubMed ID: 24022270
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
    Khan O; Rieckmann P; Boyko A; Selmaj K; Zivadinov R;
    Ann Neurol; 2013 Jun; 73(6):705-13. PubMed ID: 23686821
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
    Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
    Giovannoni G; Coyle PK; Vermersch P; Walker B; Aldridge J; Nolting A; Galazka A; Lemieux C; Leist TP
    Front Immunol; 2021; 12():763433. PubMed ID: 35003076
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y; Traboulsee A; Petkau AJ; Li D
    Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
    Kappos L; Gold R; Miller DH; MacManus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Eraksoy M; Meluzinova E; Dufek M; Yang M; Dawson K; O'Neill GN
    Mult Scler; 2012 Mar; 18(3):314-21. PubMed ID: 21878455
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
    Hermann R; Karlsson MO; Novakovic AM; Terranova N; Fluck M; Munafo A
    Clin Pharmacokinet; 2019 Mar; 58(3):283-297. PubMed ID: 29987837
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
    Romine JS; Sipe JC; Koziol JA; Zyroff J; Beutler E
    Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
    Oh J; Walker B; Giovannoni G; Jack D; Dangond F; Nolting A; Aldridge J; Lebson LA; Leist TP
    Neurodegener Dis Manag; 2022 Feb; 12(1):1-7. PubMed ID: 35019731
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.
    Freedman MS; Leist TP; Comi G; Cree BA; Coyle PK; Hartung HP; Vermersch P; Damian D; Dangond F
    Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317732802. PubMed ID: 29051829
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study.
    Borriello G; Chisari CG; Maimone D; Mirabella M; Paolicelli D; Assogna F; Caradonna S; Patti F
    Front Neurol; 2024; 15():1422078. PubMed ID: 39114529
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.